Oncosec previously showed TNBC response in the pilot study with patients treated with a checkpoint....bodes well for the combo study with Merck. Ggood results upcoming and that would be enough to get Merck thinking hard about a buyout.....they need something in TNBC to work out.
News 
Market Data 
Discover 
AI
